Biotechnology company inspired by globin chemistry and protein engineering focused on developing breakthrough antidotal therapies.
Globin Solutions, Inc. is a pre-clinical stage biopharmaceutical company that is committed to researching and developing a rapidly acting antidote for carbon monoxide poisoning, the most common human poisoning. Globin intends to aggressively develop its lead compound through preclinical testing with the goal to pursue regulatory clearance for clinical testing. Globin plans to partner with experts in globin chemistry and protein engineering through sponsored research agreements with the University of Pittsburgh to further develop their pipeline of agents for CO poisoning and other indications.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 1, 2020 | Grant | $250K | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Institutes of Health | — | Grant |